{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015259","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.867883+00:00","generated_at":"2026-06-24T02:55:12.767574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rallybio Q2 net loss $17.6M; Phase 1b RLYB212 shows platelet elimination; CFO to retire","bullets":["Net loss $17.6M ($0.57/share) vs $11.1M ($0.49) in Q2 2021 on higher R&D and G&A expenses.","Cash, equivalents and securities $147.4M as of June 30, 2022; runway into Q1 2024.","Phase 1b RLYB212 shows rapid elimination of HPA-1a positive platelets; protocol amended for broader dose range.","Phase 1 RLYB116 on track; initial single-dose data for 30 mg expected Q4 2022.","CFO Jeffrey Fryer to retire; external search for successor begun."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015259","json":"https://secwatch.observer/filing/0000950170-22-015259.json","markdown":"https://secwatch.observer/filing/0000950170-22-015259.md","text":"https://secwatch.observer/filing/0000950170-22-015259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/0000950170-22-015259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/rlyb-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:55:12.767574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}